

Soft-Tissue Sarcoma

(>= 10cm Intermediate and >= 5cm High Grade)*

INITIAL EVALUATION

H & P
 CBC, differential, platelets, total protein, albumin, calcium, phosphorous, glucose, BUN, uric acid, creatinine, total bilirubin, alkaline phosphatase, LDH, SGPT, sodium, potassium, chloride, CO₂, coag battery
 Urinalysis with microscopic (if ifosfamide)
 Plain films of primary
 CXR
 CT of Chest
 Needle biopsy (if not done outside)
 Histology review by Soft Tissue Sarcoma Pathologist
 MRI of primary (if not intra-abdominal)
 US of primary (if status post excision)
 CT of abdomen and pelvis (if Myxoid Lipo or Retroperitoneal of Pelvic Primary)
 EKG and Cardiac Scan (if cardiac history)
 CVC
 Screening MRI of spine (if Small Cell)
 Bone Scan (if indicated by history)
 Plain Film (if indicated by history)
 Sarcoma Planning Conference

TREATMENT

PRE-OP
Chemotherapy

LOCAL
THERAPY

POST-OP
Chemotherapy

1. Clinical trial
 2. Surgery and Radiation Therapy

Chemotherapy as tolerated

1. Adriamycin (Doxorubicin) (60-90mg/m²)
 2. Adriamycin (Doxorubicin) (60-90mg/m²) DIC (600-900mg/m²)
 3. CYADIC: Cyclophosphamide 750, Adriamycin (Doxorubicin) 75, DIC 750mg/m²
 4. CYVADIC
 5. Ifosfamide (10-14gm/m²)
 6. Adriamycin (Doxorubicin) (75-90mg/m²) Ifosfamide (10gm/m²)
 7. Clinical trial
 (For up to 6 cycles)

Surgery +/-
 Radiation
 Therapy
 (primary or
 mets)

Post-Op Chemo
 as tolerated

Surgery +/-
 Radiation
 Therapy
 (primary or
 mets)

Post-Op Chemo
 as tolerated

FOLLOW-UP

H & P q 2 mo for 2 yr, then q 3 mo for 2 yr, then q 4 mo for 1 yr, then q 6 mo for 1 yr, then yearly.
 CBC, differential, platelets yearly
 Total protein, albumin, calcium, glucose, creatinine, total bilirubin, alkaline phosphatase, LDH, SGPT, every other visit for 5 years, then yearly.
 CXR q 2 mo for 2 yr, then q 3 mo for 2 yr, then q 4 mo for 1 yr, then q 6 mo for 1 yr, then yearly.
 CT of Chest if CXR becomes equivocal or for surgical planning.
 US Primary (CT for intra-abdominal) q 4 mo for 2 yr, then q 6 mo for 2 yr.
 Cardiac Scan PRN.

*Not applicable to all histologies e.g. GI Leiomyo, Chondrosarcoma, Alveolar Soft-Parts Sarcoma, Clear Cell Sarcoma

Soft-Tissue Sarcoma

Physicians and nurses at The M. D. Anderson Cancer Center created this practice guideline.
The core development team included:

Dr. Robert S. Benjamin
Dr. Shreyaskumar Patel
Dr. Alan A. Pollack
Dr. Alan Yasko

MDACC